A bioluminescent tumor probe promises to give surgeons a glistening intraoperative view of the dividing line between cancerous and normal tissue.
A bioluminescent tumor probe promises to give surgeons a glistening intraoperative view of the dividing line between cancerous and normal tissue.
Dr. James M. Olson, an assistant professor of hematology-oncology, and his interdisciplinary team at Children's Hospital and Fred Hutchinson Cancer Research Center in Seattle developed the unique imaging contrast agent by attaching the peptide chlorotoxin to Cy5.5, a fluorescent molecule that emits near-infrared light.
Chlorotoxin, a component of scorpion venom, preferentially binds to cancer cells.
The researchers demonstrated in mice that brain tumors as small as 1 mm in diameter can be illuminated without lighting up surrounding tissue. CTX:Cy5.5-detected tumors involved as few as 2000 cancer cells, compared with the roughly million labeled cells needed for detection with MRI, Olson said. In a prostate cancer model, as few as 200 cancer cells traveling in a mouse lymph channel were visualized.
The study appeared in the July 15 issue of Cancer Research.
The agent's ability to distinguish cancerous cells from healthy anatomy may help surgeons avoid unnecessarily destroying normal tissue when they excise cancerous lesions. Surgical precision is particularly vital in the brain, where about 80% of malignant cancers recur at the surgical margin, he said.
CTX:Cy5.5 shows promise for imaging melanoma and skin, esophageal, cervical, lung, and colon cancers.
The agent's rapid enhancement rate and long dwell times suggest that it can be conveniently applied in clinical practice. CTX:Cy5.5 binds to cancer cells within minutes after injection, but its signal can be detected at the binding sites for 14 days.
"You can imagine somebody would receive the probe and the next day go to their dermatologist and be scanned to find out which moles are potentially precancerous or cancerous," Olson said.
The researchers are now gathering toxicity data to support an FDA application for clinical trials that could begin within 18 months. They are also developing iron oxide-based nanoparticles coated with chlorotoxin for MR imaging.
"My greatest hope is that tumor paint will fundamentally improve cancer therapy," Olson said. "By allowing surgeons to see cancers that would be undetectable by other means, we can give our patients better outcomes."
For more information from the Diagnostic Imaging archives:
CMIR blazes trail of MI discovery
3D fluorescence molecular tomography tracks genetically induced bone growth
Scientific discovery adds spice to Britton Chance's long life
Cell-tracking study opens career door as well as window on vessel disease
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Possible Real-Time Adaptive Approach to Breast MRI Suggests ‘New Era’ of AI-Directed MRI
June 3rd 2025Assessing the simulated use of AI-generated suspicion scores for determining whether one should continue with full MRI or shift to an abbreviated MRI, the authors of a new study noted comparable sensitivity, specificity, and positive predictive value for biopsies between the MRI approaches.